Verified Nov 2026
Chassis & Safety Systems
·
Brisbane, California
·
Since 2007
Pacira BioSciences, Inc. is a pharmaceutical company headquartered in Brisbane, California, United States, founded in 2007. It employs between 500 and 1,000 people and is publicly listed under the ticker PCRX. The company develops and commercializes non-opioid pain management therapies for the healthcare and veterinary sectors. Its EXPAREL® suspension, a long-acting local analgesic, is among its own-made products. In October 2026, Viatris announced an agreement to acquire the company.
Pacira BioSciences, Inc. at a glance
Revenue
726.4M
Employees
500-1,000
Founded
2007
Headquarters
Brisbane, California
Ownership
Publicly traded (NASDAQ: PCRX)
Import activity
33
Industries
Automotive
Electric Vehicles
Medical
Renewable Energy
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
33
Named foreign suppliers
9
Top origins
Belgium · China · Taiwan · Germany
Shared foreign counterparties do not establish that these companies buy from Pacira BioSciences, Inc..
What this tells a buyer
Pacira announced in January 2026 an agreement with LG Chem to make EXPAREL® available in select Asia-Pacific markets, and in October 2026 an exclusive agreement with Molteni Farmaceutici to commercialize EXPAREL® in the European Union and United Kingdom.
The company lists EXPAREL® in suspension form among its products, and its proprietary multivesicular liposome (pMVL) drug delivery technology underpins its pain therapies.
Pacira reports annual revenue in the 726.4 million band and is listed as a public company, and Viatris publicly announced a tender offer to acquire the company in October 2026.
Source: US customs bill-of-lading records and public filings · Last verified Nov 05, 2026
Overview
Pacira BioSciences, Inc. is a pharmaceutical company headquartered in Brisbane, California, United States, founded in 2007. It employs between 500 and 1,000 people and is publicly listed under the ticker PCRX. The company develops and commercializes non-opioid pain management therapies for the healthcare and veterinary sectors. Its EXPAREL® suspension, a long-acting local analgesic, is among its own-made products. In October 2026, Viatris announced an agreement to acquire the company.
At a glance
Attribute | Detail |
|---|---|
Founded | 2007 |
Headquarters | Brisbane, California |
Employees | 500-1,000 |
Revenue | 726.4M |
Ownership | Publicly traded (NASDAQ: PCRX) |
Primary capability | Chassis & Safety Systems |
What Pacira BioSciences, Inc. makes
The company lists EXPAREL® in suspension form among its products, and its proprietary multivesicular liposome (pMVL) drug delivery technology underpins its pain therapies.
Products and capabilities described on the company's own site include Suspension (source: pacira.com).
Trade and customs footprint
Pacira announced in January 2026 an agreement with LG Chem to make EXPAREL® available in select Asia-Pacific markets, and in October 2026 an exclusive agreement with Molteni Farmaceutici to commercialize EXPAREL® in the European Union and United Kingdom. US customs bill-of-lading records list 33 inbound shipments across 9 foreign suppliers, with top origins including Belgium · China · Taiwan · Germany.
Latest developments
2026-10-30 — Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc. | Viatris (viatris.com)
2026-10-08 — Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies | Pacira BioSciences, Inc. (pacira.com)
2026-10-05 — Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom | Pacira BioSciences, Inc. (pacira.com)
2026-06-30 — Pacira BioSciences Announces Agreement to Divest its (globenewswire.com)
2026-01-13 — Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets | Pacira BioSciences, Inc. (pacira.com)
2025-11-04 — Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control | Pacira BioSciences, Inc. (pacira.com)
Facilities
Pacira BioSciences, Inc. is headquartered in Brisbane, California. Public sources also reference these locations:
Swindon, United Kingdom — pacira.com
Company details
Pacira reports annual revenue in the 726.4 million band and is listed as a public company, and Viatris publicly announced a tender offer to acquire the company in October 2026. Pacira BioSciences, Inc. was founded in 2007, has an estimated 500-1,000 employees, and is headquartered in Brisbane, California.
Frequently asked questions
What does Pacira BioSciences, Inc. make?
Pacira BioSciences, Inc. is a pharmaceutical company headquartered in Brisbane, California, United States, founded in 2007. It employs between 500 and 1,000 people and is publicly listed under the ticker PCRX. The company develops and commercializes non-opioid pain management therapies for the healthcare and veterinary sectors. Its EXPAREL® suspension, a long-acting local analgesic, is among its own-made products. In October 2026, Viatris announced an agreement to acquire the company.
Where is Pacira BioSciences, Inc. headquartered?
Pacira BioSciences, Inc. is headquartered in Brisbane, California.
When was Pacira BioSciences, Inc. founded?
Pacira BioSciences, Inc. was founded in 2007.
How big is Pacira BioSciences, Inc.?
Pacira BioSciences, Inc. has an estimated 500-1,000 employees, with revenue in the 726.4M range.
Is Pacira BioSciences, Inc. publicly traded?
Publicly traded (NASDAQ: PCRX). Public financial figures are drawn from its filings.
Does Pacira BioSciences, Inc. import from overseas suppliers?
US customs bill-of-lading records show 33 inbound shipments for Pacira BioSciences, Inc., with top origins including Belgium · China · Taiwan · Germany.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile comes from a public-data sample of around 1,000 companies. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.